Trans-[bis(benzimidazol-2-ylidene)dichlorido]platinum(II) complexes with peculiar modes of action and activity against cisplatin-resistant cancer cells

Three series of cis- and trans-[bis(benzimidazol-2-ylidene)dichlorido]platinum(II) and cis-[(benzimidazol-2-ylidene)(DMSO)dichlorido]platinum(II) complexes were synthesised and screened for cytotoxicity against six human cancer cell lines. Depending on their N-alkyl and 5-alkoxycarbonyl substituents, two-digit nanomolar to single-digit micromolar IC₅₀ values against cancer cell lines intrinsically resistant to or ill-responding to cisplatin were reached by both cis- and trans-configured complexes. The stability of the complexes under aqueous biotest conditions was shown via ¹H and ¹⁹⁵Pt NMR monitoring to be dependent on their configuration and their N-substituents. Localisation studies employing click reactions with 1-alkyne- or cyclopropene-tagged derivatives revealed that the cis-complexes accumulated in the cell nuclei and the trans-complexes in the mitochondria. While the most active cis-complexes showed modes of action akin to those of cisplatin, the most active trans-complexes differed from cisplatin by much lower rates of cellular uptake and ROS production, and by their non-interaction with the cell cycle and the DNA of cancer cells. Thus, we identified structural key elements for the synthesis of optimised trans-configured NHC platinum(II) complexes with high activity also against cisplatin-refractory cancer cells.

Phosphorescent Tris-cyclometalated Pt(IV) Complexes with Mesoionic N-Heterocyclic Carbene and 2-Arylpyridine Ligands

The synthesis, structure, photophysical properties, and electrochemistry of the first series of Pt(IV) tris-chelates bearing cyclometalated aryl-NHC ligands are reported. The complexes have the general formula [Pt(trz)₂(C∧N)]⁺, combining two units of the cyclometalated, mesoionic aryl-NHC ligand 4-butyl-3-methyl-1-phenyl-1H-1,2,3-triazol-5-ylidene (trz) with a cyclometalated 2-arylpyridine [C∧N = 2-(2,4-difluorophenyl)pyridine (dfppy), 2-phenylpyridine (ppy), 2-(p-tolyl)pyridine (tpy), 2-(2-thienyl)pyridine (thpy), 2-(9,9-dimethylfluoren-2-yl)pyridine (flpy)], and presenting a mer arrangement or metalated aryls. They exhibit a significant photostability under UV irradiation and long-lived phosphorescence in the blue to yellow color range, arising from ³LC excited states involving the C∧N ligands, with quantum yields of up to 0.34 in fluid solution and 0.77 in the rigid matrix at 298 K. The time-dependent density functional theory (TD-DFT) calculations reveal that nonemissive, deactivating excited states of ligand-to-metal charge-transfer (LMCT) character are pushed to high energies as a consequence of the strong σ-donating ability of the carbenic moieties, making the Pt(trz)₂ subunit an essential structural component that enables efficient emissions from the chromophoric C∧N ligands, with potential application for the development of different Pt(IV) emitters with tunable properties.

Novel cis-[(NHC)1(NHC)2(L)Cl]platinum(ii) complexes – synthesis, structures, and anticancer activities

Platinum(ii) complexes bearing two different, cis-oriented, N-heterocyclic carbene ligands are readily accessible for catalysis or as selective, pleiotropic anticancer agents.